Berthoux F, Mohey H, Laurent B, Mariat C, Afiani A, Thibaudin L (2011) Predicting the risk for dialysis or death in IgA nephropathy. J Am Soc Nephrol 22:752–761. https://doi.org/10.1681/ASN.2010040355

Article  PubMed  PubMed Central  Google Scholar 

Li X, Liu Y, Lv J, Shi S, Liu L, Chen Y, Zhang H (2014) Progression of IgA nephropathy under current therapy regimen in a Chinese population. Clin J Am Soc Nephrol 9:484–489. https://doi.org/10.2215/CJN.01990213

Article  PubMed  PubMed Central  Google Scholar 

Barbour SJ, Espino-Hernandez G, Reich HN, Coppo R, Roberts IS, Feehally J, Herzenberg AM, Cattran DC, Derivation Oxford, Validation North American, VALIGA Consortia; Oxford Derivation North American Validation and VALIGA Consortia (2016) The MEST score provides earlier risk prediction in lgA nephropathy. Kidney Int 89:167–175. https://doi.org/10.1038/ki.2015.322

Article  CAS  PubMed  Google Scholar 

Trimarchi H, Barratt J, Cattran DC, Cook HT, Coppo R, Haas M, Liu ZH, Roberts IS, Yuzawa Y, Zhang H, Feehally J; IgAN Classification Working Group of the International IgA Nephropathy Network and the Renal Pathology Society; Conference Participants (2017) Oxford Classification of IgA nephropathy 2016: an update from the IgA Nephropathy Classification Working Group. Kidney Int 91:1014–1021. https://doi.org/10.1016/j.kint.2017.02.003

Article  Google Scholar 

Cheung CK, Alexander S, Reich HN, Selvaskandan H, Zhang H, Barratt J (2025) The pathogenesis of IgA nephropathy and implications for treatment. Nat Rev Nephrol 21:9–23. https://doi.org/10.1038/s41581-024-00885-3

Article  CAS  PubMed  Google Scholar 

Pattrapornpisut P, Avila-Casado C, Reich HN (2021) IgA Nephropathy: Core Curriculum 2021. Am J Kidney Dis 78:429–441. https://doi.org/10.1053/j.ajkd.2021.01.024

Article  CAS  PubMed  Google Scholar 

Hastings MC, Rizk DV, Kiryluk K, Nelson R, Zahr RS, Novak J, Wyatt RJ (2022) IgA vasculitis with nephritis: update of pathogenesis with clinical implications. Pediatr Nephrol 37:719–733. https://doi.org/10.1007/s00467-021-04950-y

Article  PubMed  Google Scholar 

Selvaskandan H, Cheung CK, Barratt J (2022) IgA nephropathy and IgA vasculitis. In: Harber M (ed) Primer on nephrology. Springer International Publishing, Cham, pp 451–465. https://doi.org/10.1007/978-3-030-76419-7_24

Davin J-C, Coppo R (2014) Henoch-Schönlein purpura nephritis in children. Nat Rev Nephrol 10:563–573. https://doi.org/10.1038/nrneph.2014.126

Article  CAS  PubMed  Google Scholar 

Wong K, Pitcher D, Braddon F, Downward L, Steenkamp R, Annear N, Barratt J, Bingham C, Chrysochou C, Coward RJ, Game D, Griffin S, Hall M, Johnson S, Kanigicherla D, Frankl FK, Kavanagh D, Kerecuk L et al (2024) Effects of rare kidney diseases on kidney failure: a longitudinal analysis of the UK National Registry of Rare Kidney Diseases (RaDaR) cohort. Lancet 403:1279–1289. https://doi.org/10.1016/S0140-6736(23)02843-X

Article  PubMed  PubMed Central  Google Scholar 

Suzuki H, Yasutake J, Makita Y, Tanbo Y, Yamasaki K, Sofue T, Kano T, Suzuki Y (2018) IgA nephropathy and IgA vasculitis with nephritis have a shared feature involving galactose-deficient IgA1-oriented pathogenesis. Kidney Int 93:700–705. https://doi.org/10.1016/j.kint.2017.10.019

Article  CAS  PubMed  Google Scholar 

Vincent FB, Morand EF, Schneider P, Mackay F (2014) The BAFF/APRIL system in SLE pathogenesis. Nat Rev Rheumatol 10:365–373. https://doi.org/10.1038/nrrheum.2014.33

Article  CAS  PubMed  Google Scholar 

Cheung CK, Barratt J, Liew A, Zhang H, Tesar V, Lafayette R (2023) The role of BAFF and APRIL in IgA nephropathy: pathogenic mechanisms and targeted therapies. Front Nephrol 3:1346769. https://doi.org/10.3389/fneph.2023.1346769

Article  PubMed  Google Scholar 

Zheng N, Wang D, Ming H, Zhang H, Yu X (2015) BAFF promotes proliferation of human mesangial cells through interaction with BAFF-R. BMC Nephrol 16:72. https://doi.org/10.1186/s12882-015-0064-y

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lv J, Liu L, Hao C, Li G, Fu P, Xing G, Zheng H, Chen N, Wang C, Luo P, Xie D, Zuo L, Li R, Mao Y, Dong S, Zhang P, Zheng H, Wang Y et al (2023) Randomized phase 2 trial of telitacicept in patients with IgA nephropathy with persistent proteinuria. Kidney Int Rep 8:499–506. https://doi.org/10.1016/j.ekir.2022.12.014

Article  PubMed  Google Scholar 

Liu J, Han X, Jiang X, Gao X, Li G, Fang X, Chen J, Zhai Y, Liu J, Pei Y, Zhang J, Zhu G, Shen Q, Xu H (2024) Efficacy and safety of telitacicept as an add-on therapy for refractory immunoglobulin A nephropathy or immunoglobulin A vasculitis nephropathy in children. Kidney Int Rep 10:940–943. https://doi.org/10.1016/j.ekir.2024.11.1363

Article  PubMed  PubMed Central  Google Scholar 

Liu L, Liu Y, Li J, Tang C, Wang H, Chen C, Long H, Chen X, Xing G, Cheng J, Liang J, Peng X, Wang L, Shao S, Lin Y, Chen T, Tang Y, Shen S et al (2024) Efficacy and safety of telitacicept in IgA nephropathy: a retrospective, multicenter study. Nephron 149:1–10. https://doi.org/10.1159/000540326

Article  CAS  PubMed  Google Scholar 

Schwartz GJ, Schneider MF, Maier PS, Moxey-Mims M, Dharnidharka VR, Warady BA, Furth SL, Muñoz A (2012) Improved equations estimating GFR in children with chronic kidney disease using an immunonephelometric determination of cystatin C. Kidney Int 82:445–453. https://doi.org/10.1038/ki.2012.169

Article  CAS  PubMed  PubMed Central  Google Scholar 

Counahan R, Winterborn MH, White RH, Heaton JM, Meadow SR, Bluett NH, Swetschin H, Cameron JS, Chantler C (1977) Prognosis of Henoch-Schönlein nephritis in children. Br Med J 2:11–14. https://doi.org/10.1136/bmj.2.6078.11

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang J, Cui J, Chen J, Liao Y, Yang M, Lin J, Yang X, Zhao B (2025) Telitacicept use in children with IgA vasculitis nephritis: preliminary observations. Pediatr Nephrol. https://doi.org/10.1007/s00467-025-06709-1

Article  PubMed  PubMed Central  Google Scholar 

Jin Y, Zhu J, Sheng A, Lin Q, Zhao M, He X, Mao J, Fu H (2025) Telitacicept as a BAFF/APRIL dual inhibitor: efficacy and safety in reducing proteinuria for refractory childhood IgA vasculitis nephritis. Pediatr Nephrol 40:2561–2569. https://doi.org/10.1007/s00467-025-06769-3

Article  PubMed  Google Scholar 

Su B, Jiang Y, Li Z, Zhou J, Rong L, Feng S, Zhong F, Sun S, Zhang D, Xia Z, Feng C, Huang W, Li X, Chen C, Hao Z, Wang M, Qin L, Chen M et al (2024) Are children with IgA nephropathy different from adult patients? Pediatr Nephrol 39:2403–2412. https://doi.org/10.1007/s00467-024-06361-1

Article  PubMed  PubMed Central  Google Scholar 

Barratt J, Barbour SJ, Brenner RM, Cooper K, Wei X, Eren N, Floege J, Jha V, Kim SG, Maes B, Phoon RKS, Singh H, Tesař V, Lafayette R, Phase ORIGIN, 2b Investigators (2025) Long-term results from an open-label extension study of atacicept for the treatment of IgA nephropathy. J Am Soc Nephrol 36:679–687. https://doi.org/10.1681/ASN.0000000541

Floege J, Bernier-Jean A, Barratt J, Rovin B (2025) Treatment of patients with IgA nephropathy: a call for a new paradigm. Kidney Int 107:640–651. https://doi.org/10.1016/j.kint.2025.01.014

Article  CAS  PubMed  Google Scholar 

Fan Y, Gao D, Zhang Z (2022) Telitacicept, a novel humanized, recombinant TACI-Fc fusion protein, for the treatment of systemic lupus erythematosus. Drugs Today (Barc) 58:23–32. https://doi.org/10.1358/dot.2022.58.1.3352743

Article  PubMed  Google Scholar 

Cai J, Gao D, Liu D, Liu Z (2023) Telitacicept for autoimmune nephropathy Front Immunol 14:1169084. https://doi.org/10.3389/fimmu.2023.1169084

Article  CAS  PubMed  Google Scholar 

Dhillon S (2021) Telitacicept: first approval. Drugs 81:1671–1675. https://doi.org/10.1007/s40265-021-01591-1

Article  CAS  PubMed  Google Scholar 

Shi F, Xue R, Zhou X, Shen P, Wang S, Yang Y (2021) Telitacicept as a BLyS/APRIL dual inhibitor for autoimmune disease. Immunopharmacol Immunotoxicol 43:666–673. https://doi.org/10.1080/08923973.2021.1973493

Article  CAS  PubMed  Google Scholar 

Liang D, Li X (2023) Efficacy and safety of telitacicept in patients with IgA nephropathy. Pak J Med Sci 39:1897. https://doi.org/10.12669/pjms.39.6.8393

Sun L, Shen Q, Gong Y, Li Y, Lv Q, Liu H, Zhao F, Yu H, Qiu L, Li X, He X, Chen Y, Xu Z, Xu H (2022) Safety and efficacy of telitacicept in refractory childhood-onset systemic lupus erythematosus: a self-controlled before-after trial. Lupus 31:998–1006. https://doi.org/10.1177/09612033221097812